ERBB2 and breast cancer: Specifically, epidermal growth factor receptor (EGFR) inhibitors are clearly effective clinically in the treatment of EGFR mutant lung cancer (Ramalingam et al., 2020), and HER2 inhibitors are active in HER2-positive breast cancer (Cortes et al., 2022) (Park et al., 2009).